Hence, there has been only one partial response reported among the 46 evaluable patients treated in these two trials for an aggregate response rate of 2% and a median time to progression of less than 8 weeks.
The term 'dedifferentiation' has been reported as a progression of cells towards a less differentiated state with no longer the original line of differentiation (Dahlin and Beabout, 1971).
Such shifts also correspond to changes in how the human species understands, and subsequently harnesses, varying forms of energy, upon a progression of discovering ever-finer and less dense/corrosive forms of energy.
Conventional chemotherapy regimens produce 40 to 80% objective response rates with median time to progression of less than 1 year (Clavel and Catimel, 1993; Nabholtz et al, 2001).
The Edinburgh Type 2 Diabetes Study is a large prospective cohort study that has the potential to identify factors that are important for the development and progression of less well-characterised complications of type 2 diabetes.
To evaluate the association between an increase in biomarkers and OS duration, patients were grouped into four categories: (1) time to progression of less than 3 months, (2) time to progression of 3 6 months, (3) time to progression of 6-12 months, and (4) no progression greater than 12 months.
Though Kübler-Ross captured the range of emotions that mourners experience, new research suggests that grief and mourning don't follow a checklist; they're complicated and untidy processes, less like a progression of stages and more like an ongoing process — sometimes one that never fully ends.
No group could be defined with a freedom from progression rate of less than 70% over 6-18 months, and the worst prognostic group, which included only 53 patients, had an overall freedom from progression rate of 57% at 5 years.
29 Other studies have confirmed cardiorespiratory fitness as a predictor of less progression towards the MS 7 10 even in high-risk individuals.
Relatively little is known about the risk factors associated with the development and progression of these less prominent diabetes-related complications, although factors such as poor glycaemic control, increased inflammation, abnormal glucocorticoid metabolism and microangiopathy may be important [ 8- 12].
While the beneficial effects of TKIs are significant, strategies to enhance and/or prolong the effect of these agents are of importance as responses are almost exclusively partial and tumours develop tumour progression on therapy at a median of less than 1 year.
